Bayer, GE, Mallinckrodt, and Bracco named in latest gadolinium suit
The complaint filed March 3 in U.S. District Court Northern District of California names GE Healthcare, Mallinckrodt, and Bracco Diagnostics as defendants, in addition to Bayer.
According to the complaint, the plaintiffs, William and Patricia Paschal, alleged that William Paschal contracted nephrogenic systemic fibrosis (NSF) in January through intravenous injections containing the gadolinium-based contrast that is manufactured and sold by defendants.
NSF, also known as nephrogenic fibrosing dermopathy (NSD), has been shown to occur in patients presenting with renal insufficiency who undergo an MRI exam that employs a gadolinium-based contrast agent.
The Paschals’ attorneys allege that the defendants never tested the compound's safety on individuals with kidney impairments before marketing it; however they stated that tests conducted on animals showed internal and external scarring.
The San Francisco-based law firm said that the complaint charges the defendants with failure to warn, design defect, failure to adequately test, negligence, negligent misrepresentation, fraud, concealment, suppression or omission of material facts, breach of express and implied warranty and loss of consortium.